Haverford Trust Co Has $350,000 Stock Holdings in Solventum Co. (NYSE:SOLV)

Haverford Trust Co decreased its position in shares of Solventum Co. (NYSE:SOLV) by 22.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 5,013 shares of the company’s stock after selling 1,449 shares during the quarter. Haverford Trust Co’s holdings in Solventum were worth $350,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Victory Capital Management Inc. grew its position in shares of Solventum by 137.3% during the 3rd quarter. Victory Capital Management Inc. now owns 53,589 shares of the company’s stock worth $3,736,000 after buying an additional 31,007 shares during the period. Los Angeles Capital Management LLC grew its holdings in Solventum by 670.0% during the third quarter. Los Angeles Capital Management LLC now owns 40,888 shares of the company’s stock valued at $2,851,000 after purchasing an additional 35,578 shares during the period. Sigma Planning Corp bought a new stake in Solventum in the third quarter valued at approximately $241,000. Covestor Ltd raised its holdings in Solventum by 822.6% in the third quarter. Covestor Ltd now owns 2,740 shares of the company’s stock worth $191,000 after purchasing an additional 2,443 shares during the period. Finally, Atria Investments Inc raised its holdings in Solventum by 93.2% in the third quarter. Atria Investments Inc now owns 11,699 shares of the company’s stock worth $816,000 after purchasing an additional 5,644 shares during the period.

Solventum Stock Performance

Shares of Solventum stock opened at $67.93 on Friday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The business’s 50 day moving average is $70.46 and its 200-day moving average is $62.17.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on SOLV shares. Morgan Stanley increased their price target on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday. The Goldman Sachs Group increased their target price on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a report on Monday, August 12th. Wolfe Research began coverage on Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating on the stock. Piper Sandler increased their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Finally, BTIG Research started coverage on Solventum in a research note on Thursday, September 5th. They issued a “neutral” rating on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Solventum presently has an average rating of “Hold” and an average target price of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.